Jiangsu Chinagreen Biological Technology Group Co.,Ltd. (SHE:300970)
China · Delayed Price · Currency is CNY 36.30
+0.40 (1.11%)
At close: Apr 29, 2026
SHE:300970 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,436 | 1,292 | 1,032 | 996.22 | 751.58 | 578.08 |
Other Revenue | - | - | - | - | 0.02 | 0 |
| 1,436 | 1,292 | 1,032 | 996.22 | 751.59 | 578.09 | |
Revenue Growth (YoY) | 37.27% | 25.17% | 3.60% | 32.55% | 30.01% | -5.14% |
Cost of Revenue | 1,114 | 1,084 | 982.52 | 870.12 | 632.47 | 539.94 |
Gross Profit | 321.08 | 207.98 | 49.59 | 126.1 | 119.12 | 38.15 |
Selling, General & Admin | 69.4 | 69.3 | 78.37 | 80.18 | 49.29 | 37.25 |
Research & Development | 19.13 | 17.37 | 14.61 | 16.53 | 14.04 | 8.62 |
Other Operating Expenses | -12.99 | -13.19 | -8.14 | -7.91 | 0.53 | 0.41 |
Operating Expenses | 75.55 | 73.49 | 86.44 | 89.32 | 64.29 | 46.72 |
Operating Income | 245.53 | 134.5 | -36.85 | 36.78 | 54.83 | -8.58 |
Interest Expense | - | - | -11.18 | -8.75 | -2.69 | -3.83 |
Interest & Investment Income | - | - | 3.37 | 9.18 | 16.7 | 16.21 |
Currency Exchange Gain (Loss) | - | - | - | - | - | 0 |
Other Non Operating Income (Expenses) | -7.25 | -13.2 | 0.27 | 1.8 | -0.39 | -0.2 |
EBT Excluding Unusual Items | 238.28 | 121.3 | -44.4 | 39.01 | 68.44 | 3.6 |
Gain (Loss) on Sale of Investments | - | - | - | -0.17 | -0.06 | 0.24 |
Gain (Loss) on Sale of Assets | -1.94 | -2.15 | -1.48 | -10.89 | -1.33 | -0.26 |
Asset Writedown | 0.27 | 0.15 | -1 | -3.57 | -0.36 | - |
Other Unusual Items | - | - | 2.6 | 2 | 13.29 | 13.21 |
Pretax Income | 236.61 | 119.31 | -44.28 | 26.37 | 79.99 | 16.79 |
Income Tax Expense | 0.05 | 0.05 | 0.15 | 0 | 2.32 | 0.51 |
Earnings From Continuing Operations | 236.56 | 119.26 | -44.42 | 26.37 | 77.67 | 16.28 |
Minority Interest in Earnings | -17.95 | -8.99 | -3.14 | 3.98 | 0.59 | -0.78 |
Net Income | 218.62 | 110.27 | -47.57 | 30.35 | 78.25 | 15.5 |
Net Income to Common | 218.62 | 110.27 | -47.57 | 30.35 | 78.25 | 15.5 |
Net Income Growth | - | - | - | -61.22% | 404.70% | -88.30% |
Shares Outstanding (Basic) | 110 | 119 | 116 | 117 | 117 | 111 |
Shares Outstanding (Diluted) | 110 | 119 | 116 | 117 | 117 | 111 |
Shares Change (YoY) | -17.11% | 2.20% | -0.61% | -0.06% | 5.46% | 8.66% |
EPS (Basic) | 1.98 | 0.93 | -0.41 | 0.26 | 0.67 | 0.14 |
EPS (Diluted) | 1.98 | 0.93 | -0.41 | 0.26 | 0.67 | 0.14 |
EPS Growth | - | - | - | -61.19% | 378.57% | -89.23% |
Free Cash Flow | 330.38 | 222.19 | -130.42 | -57.48 | -228.07 | -121.01 |
Free Cash Flow Per Share | 3.00 | 1.87 | -1.12 | -0.49 | -1.95 | -1.09 |
Dividend Per Share | - | - | - | 0.200 | 0.200 | - |
Gross Margin | 22.37% | 16.10% | 4.81% | 12.66% | 15.85% | 6.60% |
Operating Margin | 17.10% | 10.41% | -3.57% | 3.69% | 7.29% | -1.48% |
Profit Margin | 15.23% | 8.54% | -4.61% | 3.05% | 10.41% | 2.68% |
Free Cash Flow Margin | 23.02% | 17.20% | -12.64% | -5.77% | -30.34% | -20.93% |
EBITDA | 417.8 | 300.4 | 103.61 | 154.31 | 151.79 | 75.92 |
EBITDA Margin | 29.10% | 23.25% | 10.04% | 15.49% | 20.20% | 13.13% |
D&A For EBITDA | 172.27 | 165.91 | 140.45 | 117.53 | 96.96 | 84.49 |
EBIT | 245.53 | 134.5 | -36.85 | 36.78 | 54.83 | -8.58 |
EBIT Margin | 17.10% | 10.41% | -3.57% | 3.69% | 7.29% | -1.48% |
Effective Tax Rate | 0.02% | 0.04% | - | - | 2.90% | 3.02% |
Revenue as Reported | - | - | 1,032 | 996.22 | 751.59 | 578.09 |
Advertising Expenses | - | - | 0.45 | 0.26 | 0.03 | 0.89 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.